Acute myeloid leukemia (AML) is a highly heterogenous disease with multiple signaling pathways contributing to its pathogenesis. A key driver of AML is the FMS-like tyrosine kinase receptor-3 (FLT3). Activating mutations in FLT3, primarily the FLT3-internal tandem duplication (FLT3-ITD), are associated with decreased progression-free and overall survival. Identification of the importance of FLT3-ITD and the FLT3 pathway in the prognosis of patients with AML has stimulated efforts to develop therapeutic inhibitors of FLT3. Although these inhibitors have shown promising antileukemic activity, they have had limited efficacy to date as single agents and may require use in combination with cytotoxic chemotherapies. Here, we review clinical and preclinical results for the clinically mature FLT3 inhibitors currently in development. We conclude that multitargeted FLT3 inhibitors may have more utility earlier in the course of disease, when in vitro evidence suggests that AML cells are less dependent on FLT3 signaling, perhaps because of upregulation of multiple other signaling pathways. More potent agents may have greater utility in relapsed and heavily pretreated patients, in whom high levels of circulating FLT3 ligand may necessitate use of an agent with a very favorable pharmacokinetic/ pharmacodynamic profile. Novel combination regimens are also discussed.
INTRODUCTION
Adult acute myeloid leukemia (AML) accounts for B30% of leukemias and 440% of leukemia-related deaths.
1 AML is a highly heterogenous disease characterized by several karyotypic abnormalities (Table 1) . 2, 3 Karyotypic abnormalities associated with a relatively good prognosis are present in B15% of patients and include translocation of chromosomes 15 and 17, t(15;17) (q22;q21), translocation of chromosomes 8 and 21, t(8;21) (q22;q22) and inversion of chromosome 16, inv(16)(p13q22)/ t(16;16)(p13;q22). Prognostically bad karyotypic abnormalities, also present in B15% of patients, include deletion of chromosome 7, deletion of chromosome 5q and more than three chromosomal abnormalities. 4, 5 Other karyotypic abnormalities that have an unclear effect on prognosis have been observed, including trisomy 8 and trisomy 21d. These abnormalities are generally considered to be in the intermediate-risk prognosis category along with normal karyotype. The identification of these markers led to the development of cytogenetic risk classification systems by several cooperative groups internationally, including the Cancer and Leukemia Group B, 5 Eastern Cooperative Oncology and Southwest Oncology Groups, 6 the UK Medical Research Council 2 and Frö hling et al. 4 in Germany. Most patients with AML have poor rates of survival, particularly those with a poor-risk karyotype. Five-year survival rates are B55%, 24% and 5% in patients with favorable-, intermediate-and poor-risk cytogenetics, respectively. 5 Even among patients with normal karyotype AML, however, clinical outcomes are heterogenous. Among other patient-related factors, mutations in key genes involved in AML pathogenesis lead to large interpatient variability in prognostic risk (Table 2) . [7] [8] [9] There is a plethora of mutations associated with poor prognosis in AML. These include internal tandem duplication (ITD) in the FMS-like tyrosine kinase receptor-3 gene (FLT3), 10 partial tandem duplication in the mixed lineage leukemia gene, 11 Wilms tumor gene mutations 12 and overexpression of the BAALC gene. 13 Other mutations that may be associated with poor prognosis in patients with AML include 10-11-translocation oncogene family member 2, isocitrate dehydrogenase-1, isocitrate dehydrogenase-2 and additional sex comb-like 1. 14 Alternatively, CCAAT/enhancer-binding protein a (CEBPA) and nucleophosmin 1 (NPM1) mutations (in FLT3-ITD-negative patients) have been associated with improved prognosis. 14, 15 In this review, we evaluate the prognostic implications of gene mutations and cytogenetic risk factors in patients with AML, focusing on the FLT3-ITD mutation. We discuss established and emerging approaches using FLT3 inhibitors for the treatment of AML.
STRUCTURE/FUNCTION OF THE FLT3 RECEPTOR FLT3 receptor
Mutations in FLT3 are among the most commonly occurring and clinically relevant mutations in patients with AML. FLT3 is a receptor tyrosine kinase expressed on the leukemic blasts of 70-100% of patients with AML 16, 17 that is increasingly recognized as having a role in the pathogenesis of this disease. Upon binding of the FLT3 ligand, FLT3 dimerizes and undergoes a conformational change whereby its activation loop opens, revealing the ATPbinding pocket. The receptor becomes autophosphorylated, inducing cell growth and inhibiting apoptosis through the activation of a signaling cascade involving proteins such as the Ras-GTPase-activating protein, phospholipase C, signal transducer and activator of transcription 5 and ERK1/2 ( Figure 1 ). 18 Whereas, FLT3 ligand is ubiquitously expressed, 19, 20 the FLT3 receptor is localized primarily in hematopoietic and neural tissues. 21 FLT3 is integral to hematopoiesis through its regulation of proliferation, differentiation and apoptosis of hematopoietic progenitor cells. Knockout mice models have shown that lack of FLT3 ligand and FLT3 leads to reduced hematopoietic precursors, 22, 23 demonstrating the importance of these proteins in hematopoietic expansion.
FLT3 mutations
Several different mutations can occur in the FLT3 receptor in patients with AML. The most common of these is an ITD on exon 14 of the FLT3 gene, which varies from 3 to 4400 base pairs but is typically in frame and occurs in the juxtamembrane region of the receptor. 24 The ITD disrupts the autoinhibitory function of the juxtamembrane domain, resulting in constitutive autophosphorylation of FLT3 and activation of its downstream effectors. 25, 26 The FLT3-ITD mutation produces growth factor-independent proliferation in leukemia cell lines and a fatal myeloproliferative syndrome in murine models. 27 Interestingly, however, when FLT3-ITD was expressed in cells from knockout mice lacking FLT3 ligand, the receptor was only weakly activated. 28 This suggests that the ITD leads to gain of function mainly by inducing hyperresponsivity of the FLT3 receptor to FLT3 ligand rather than through autoactivation of the receptor.
Activating mutations within the kinase domain of FLT3 are also observed in patients with AML. The most common is mutation of the aspartate 835 (D835) mutation in the activation loop of the tyrosine kinase domain, which occurs in B7% of patients with AML. 29, 30 FLT3 IN THE CLINIC It has become clear that the presence of FLT3-ITD, which is observed in B25% of patients with AML, 31, 32 is a key indicator of poor long-term prognosis. This has led to a concerted effort to 
Role of FLT3 in AML R Swords et al identify therapeutic inhibitors of FLT3. Several of these agents are currently in clinical trials and have shown promising antileukemic activity. The presence of FLT3-ITD, however, is not the only relevant factor in determining patient outcome. AML is a complex disease characterized by multiple genetic abnormalities that likely interact with one another. Understanding how the myriad signaling pathways underlying the pathogenesis of AML interact with one another will be critical in determining how particular genetic abnormalities affect prognosis and response to therapy.
FLT3 as a prognostic marker
The presence of the FLT3-ITD mutation was determined to have a negative effect on long-term outcomes based on an analysis of 854 patients enrolled in Medical Research Council trials in the United Kingdom. 31 These findings were subsequently confirmed in numerous other trials. [33] [34] [35] [36] [37] In general, patients with FLT3-ITD AML achieve complete remission rates comparable to those of patients with wild-type disease, but have significantly higher rates of relapse and shorter durations of disease-free and overall survival (OS). 31, [33] [34] [35] In the Medical Research Council studies, patients with FLT3-ITD AML had a 74% relapse rate vs 48% for patients with FLT3-wild-type AML. 31 The 5-year OS rate was 32% for patients with FLT3-ITD AML vs 44% for patients with FLT3-wildtype AML; 31 event-free survival was 20 vs 41 weeks, respectively (Po0.00001). 32 In vitro evidence suggests that FLT3-ITD may contribute to drug resistance. FLT3-ITD-expressing murine and human myeloid cell lines are resistant to cytosine arabinoside (ara-C), an essential agent in AML chemotherapy regimens, and both cell lines have downregulated equilibrative nucleoside transporter 1 (ENT1), a protein responsible for the cellular uptake of ara-C. 38 Decreased levels of ENT1 may be related to the upregulation of hypoxiainducible factor 1 a subunit observed in these cells. Hypoxiainducible factor 1 a subunit is known to downregulate the promoter activity of the ENT1 gene. Pretreatment with the FLT3 inhibitor midostuarin (PKC412) rescued the ENT1 promoter activity and cellular uptake of ara-C in the human myeloid cell line, suggesting that FLT3 inhibitors may have a role in preventing resistance to the cytotoxic chemotherapy regimens used in the treatment of AML.
Although activating point mutations in the FLT3 tyrosine kinase domain have been grouped with FLT3-ITD in trial stratification schemes and when discussing FLT3 in AML, these point mutations have shown minimal prognostic implications in the absence of FLT3-ITD. 32, 39 Mutations in the tyrosine kinase domain of FLT3 frequently occur in patients with prognostically favorable NPM1 mutations, which further complicates analyses of their impact on patient outcomes. 40, 41 In fact, a study of 1107 adult patients with AML showed improved survival in patients with FLT3 tyrosine kinase domain mutations vs patients with wild-type FLT3. 42 Frequently, patients with AML have mutations in more than one gene, further complicating prediction of their prognoses. Mutations in NPM1 are the most commonly observed gene abnormalities in patients with AML, occurring in B50% of patients. 41 Patients with an NPM1 mutation and wild-type FLT3 have the highest likelihood of long-term relapse-free, event-free and OS vs all other patients. 43 However, NPM1 mutations predict better outcomes only in the absence of FLT3-ITD. 44 Patients who
C/EBP a is a transcription factor that is crucial for the differentiation of mature granulocytes. CEBPA gene mutations likely to induce differentiation arrest have been described in B10% of patients with AML. 45 In a retrospective study of 135 patients with AML, 22 CEBPA mutations were present only in patients (n ¼ 15) with intermediate-risk cytogenetics. OS was longer in patients with CEBPA-mutated AML compared with those with CEBPA-nonmutated AML (5-year OS, 53% vs 25%; P ¼ 0.04). In patients with a CEBPA mutation, the presence of FLT3-ITD mutation was associated with poorer 5-year OS compared with patients with wild-type FLT3 (20% vs 69%, P ¼ 0.03). 45 Consistent with other studies, 46 the presence of CEBPA mutations was identified as an independent predictor of good prognosis even after adjustment for cytogenetics and FLT3 status in multivariate analysis. 
18
A recent study of 481 patients with AML treated at the MD Anderson Cancer Center suggested that FLT3-ITD mutations led to worse survival in patients with normal karyotype AML but did not have a prognostic impact in patients with AML who had favorableor poor-risk karyotypes. 32 In addition, both the length 47 and location 10 of ITD insertions can negatively affect the prognostic outcome of patients, as can the absence of the wild-type allele in FLT3-ITD-positive patients, 48 whereas stem cell transplantation can improve patient survival. 49 These data emphasize the complex interactions between the numerous karyotypic abnormalities, patient-related factors and mutations found in patients with AML.
FLT3 inhibitors
Recognition of the importance of FLT3 in the pathogenesis and prognosis of patients with AML led to investigations aimed at identifying inhibitors of this tyrosine kinase. Several smallmolecule inhibitors of FLT3 currently in development demonstrate various degrees of FLT3 inhibition and clinical efficacy (Table 3) . These agents are typically classified by their affinity for FLT3, with midostaurin, lestaurtinib (CEP701) and sorafenib grouped as multitargeted tyrosine kinases, and other less clinically advanced agents such as quizartinib (AC220) and tandutinib (MLN518) considered more specific for FLT3. It has become clear, however, that predicting responses to FLT3 inhibitors is a complicated endeavor. Drug-related factors including potency for FLT3 inhibition, the ability to target other enzymes and pathways, pharmacokinetic properties, the FLT3 ligand's ability to influence the activity of kinase inhibitors and the ability to target the leukemic stem cell must be considered, as must patient-related factors such as disease state, concomitant medications and comorbidities.
Midostaurin
Midostaurin is a broad-spectrum tyrosine kinase inhibitor of wildtype and mutated FLT3 as well as other kinases involved in the pathogenesis of AML, including c-KIT, vascular endothelial growth factor receptor-2 and platelet-derived growth factor receptor. 50 In a phase 1 study of various advanced solid tumors, doses up to 75 mg thrice daily were tolerable and associated with FLT3 inhibition in vivo. 51 Subsequent studies using in vitro kinase assays and cell lines expressing FLT3-ITD demonstrated that midostaurin inhibited activated FLT3 in the nanomolar range and that FLT3 was the major target of midostaurin in these leukemia cells. 50 The 75-mg thrice daily dose was evaluated in a phase 2 study of 20 patients with FLT3-mutant AML. Midostaurin at this dose was generally well tolerated by these patients, with X50% reduction in peripheral blasts achieved in 14 patients (70%). In all, 7 of these 14 patients achieved a X2-log reduction in blasts lasting X4 weeks, and 1 patient achieved a near-complete remission (bone marrow cellularity of 10%). 52 These promising results prompted the initiation of a phase 2b trial of midostaurin at 50 or 100 mg twice daily in patients with myelodysplastic syndromes or FLT3-mutant or -wild-type AML. In this trial, midostuarin was associated with bone marrow/peripheral blood blast reduction in 71% of patients with FLT3-mutant AML and in 42% of patients with FLT3-wild-type AML. 53 Although blast reductions were achieved in a majority of patients, only one patient achieved a partial response. 53 The authors concluded that the clinical activity of midostaurin in this population supported further evaluation of midostaurin in combination with chemotherapy.
Midostaurin in combination with daunorubicin and cytarabine was associated with high rates of complete remission in newly diagnosed patients with FLT3-wild-type (20 of 27; 74%) or -mutant (12 of 13; 92%) AML in a phase 1b trial. 54 OS rates for patients with FLT3 mutations were comparable to that of patients with the more favorable FLT3-wild-type allele. The first randomized phase 3 trial testing the impact of an FLT3 inhibitor in frontline therapy (Cancer and Leukemia Group B 10603; RATIFY) has just completed accrual. This international, double-blind, placebo-controlled trial for newly diagnosed adults (o60 years) with FLT3-mutated AML evaluates standard induction and postremission chemotherapy with 56 Lestaurtinib has demonstrated clinical activity against both wild-type and mutated FLT3 (FLT3-ITD and FLT3-D835 mutations). 56 Like midostaurin, the activity of lestaurtinib as a single agent was limited primarily to bone marrow and peripheral blood blast reduction. The modest but clinical activity observed with the single agent and the in vitro synergy of this agent with chemotherapy in killing FLT3-mutant AML cells 59 supported further evaluations of lestaurtinib in combination with cytotoxic regimens.
Surprisingly, in a multicenter trial of patients with relapsed AML randomized to re-induction chemotherapy alone or chemotherapy followed by lestaurtinib, the addition of lestaurtinib did not result in higher response rates or longer OS times in these patients with advanced disease. 60 A major strength of this phase 2 study is that it incorporated correlative studies in which all samples were assayed for FLT3 plasma inhibitory activity, FLT3 ligand levels and a-1 acid glycoprotein levels. The plasma inhibitory activity assay has become a standard in the field as a surrogate for determining FLT3 inhibition in patients receiving FLT3 inhibitors. Plasma inhibitory activity analysis revealed that only 58% of patients receiving lestaurtinib achieved target FLT3 inhibition by day 15 of therapy. Complete remission rates were significantly higher in these patients than in patients without FLT3 inhibition at aplasia assessment (39% vs 9%; P ¼ 0.004).
Whereas complete remission rates correlated with FLT3 inhibition in the lestaurtinib combination trial, this response outcome was not well correlated with drug levels. 60 This may have been related to elevations in plasma FLT3 ligand and a-1 acid glycoprotein levels in response to chemotherapy. 61 Samples from patients in four separate lestaurtinib trials demonstrated that FLT3 ligand levels rise substantially after induction chemotherapy. This was particularly apparent in relapsed patients, who had mean FLT3 ligand levels of 1148 pg/ml on day 15 of induction therapy vs 488 pg/ml in newly diagnosed patients. FLT3 ligand levels rose even higher with subsequent courses of chemotherapy, to a mean of 3251 pg/ml after the fourth course. In vitro experiments demonstrated that FLT3 ligand at similar concentrations to those observed in patients diminished FLT3 inhibition and cytotoxicity for all FLT3 inhibitors tested (lestaurtinib, midostaurin, sorafenib, KW-2449 and quizartinib).
Although statistical comparisons were not done, there was a trend toward improved outcomes among younger patients treated with lestaurtinib in the phase 2 trial. 60 Taken together, these findings suggest that FLT3 inhibitors may have better efficacy in younger patients and those with newly diagnosed disease and minimal prior chemotherapy, in whom FLT3 ligand upregulation may not be as prevalent. The Medical Research Council is currently conducting two similar studies with lestaurtinib (AML 15 and 17). These studies include younger patients, both relapsed and newly diagnosed, who may have less FLT3 ligand upregulation. Early results suggested a high rate of target inhibition and complete remission in evaluable samples. 62 Sorafenib A multitargeted tyrosine kinase inhibitor of FLT3, c-KIT, NRAS, RAF and others, sorafenib is approved for the treatment of advanced renal cell and heptatocellular carcinomas. 63 Small phase 1 studies and case reports showed reduction in bone marrow blasts and acceptable tolerability with single-agent sorafenib in patients with AML. [64] [65] [66] [67] In a phase 1/2 trial of sorafenib in combination with cytarabine and idarubicin-based induction in 51 newly diagnosed patients with AML, complete remissions were achieved by 38 patients (75%). Complete remission rates were particularly high among patients with FLT3-ITD AML (14 of 15; 93%). 68 However, these positive results were not confirmed in a European placebo-controlled, randomized trial of sorafenib combined with standard induction, consolidation and maintenance in 197 elderly patients with AML. The combination was well tolerated, but no benefit for sorafenib was observed in complete remission, event-free survival or OS, even in patients with mutant FLT3-ITD AML (although this subgroup was small). 69 Trials with sorafenib are ongoing in patients with AML, including two trials focused exclusively on patients with FLT3-ITD disease, a phase 2 trial in elderly patients and a phase 3 study in pediatric patients.
Quizartinib (AC220)
Quizartinib is a second-generation FLT3 inhibitor that is highly selective for FLT3-ITD 70 as well as non-ITD FLT3 mutations and the c-KIT kinase. 71 Quizartinib was developed expressly to be an FLT3 inhibitor and is more potent and specific in vitro than the broadly targeted agents such as midostaurin, lestaurtinib and sorafenib. 70 Pharmacokinetic data from a dose-escalation study showed that quizartinib is well tolerated at doses up to 450 mg and has good oral bioavailability and a long effective half-life (1.5 days) and that quizartinib exposure is maintained between doses in patients with AML. 72 Quizartinib has shown activity in a phase 1 trial in patients with relapsed/refractory AML (N ¼ 76). 73 Responses according to the International Working Group criteria were observed in 23 patients (30%), and complete responses were observed in 10 (13%). The most commonly reported possibly drug-related adverse events were gastrointestinal events, peripheral edema and dysguesia (mostly grade 1 or 2). The maximum tolerated dose was established as 200 mg continuous dosing in this study as grade 3 QTc prolongation was observed at the 300-mg continuous dosing dose. A phase 2 study in relapsed/refractory patients with FLT3-ITD AML is currently recruiting patients, with interim data supporting doses of quizartinib 135 and 90 mg in men and women, respectively, due to QTc prolongation at a starting dose of 200 mg. 74 Tandutinib (MLN518) Tandutinib is more selective for FLT3 than midostaurin or lestaurtinib, although it does have some activity against plateletderived growth factor receptor-b and c-KIT. 75 Although tandutinib demonstrated some antileukemic activity as a single agent and in combination with chemotherapy in phase 1 studies, 76, 77 doselimiting muscle weakness (reversible) and high rates of nausea and vomiting were observed. This may be related to the slow clearance and resultant high plasma levels of the drug. Low potency and unfavorable pharmacokinetics have thus limited the clinical utility of the drug for the treatment of AML.
Lessons learned from FLT3 laboratory/clinical studies The prognostic implications of FLT3-ITD and response to FLT3 inhibitors are dependent on numerous patient-and drug-related factors, including allele burden, 32, 78 the presence of other mutations, 32 stage of disease and drug pharmacokinetics. Among these, allele burden of FLT3-ITD is a key predictor of response to FLT3 inhibitor therapy. 79, 80 In vitro studies of FLT3-ITDpositive cell lines demonstrated that relapsed samples and samples with a high mutant allele burden were more likely to be responsive to cytotoxicity from FLT3 inhibition compared with the samples obtained at diagnosis or those with a low mutant allele burden. 78 In these samples with lower FLT3-ITD allele burden, inhibition of FLT3 activity frequently did not result in cell death, suggesting that AML in patients with earlier stage disease and lower FLT3-ITD allele burden may not be addicted to FLT3 signaling for survival and proliferation. This hypothesis will be evaluated further in the prospective, phase 3 trial of midostaurin in combination with cytarabine/daunorubicin, in which younger patients with FLT3-mutant AML were stratified by FLT3-ITD allele ratio at baseline. 55 In newly diagnosed patients with AML, targeting additional tyrosine kinases that contribute to the pathogenesis of AML (other than FLT3) may be more important than the potency of the agent toward FLT3-ITD receptors. Patients with FLT3-wild-type AML, for example, had substantial responses to midostaurin in the phase 1b study, 54 suggesting that they derived clinical benefit from the multitargeted profile of this agent. Lestaurtinib has also shown in vitro cytotoxicity toward FLT3-wild-type AML, whereas sunitinib and quizartinib display minimal cytotoxicity toward FLT3-wild-type samples. 78 Likewise, the in vitro cytotoxicity dose-response curves of lestaurtinib were similar in diagnostic vs relapsed samples, unlike those of sorafenib and, even more so, quizartinib, for which relapsed samples, in which potent FLT3 inhibition may be more important, were considerably more responsive than samples obtained at diagnosis. Other in vitro studies have confirmed the association between the nonselectivity of the FLT3 inhibitors midostaurin and lestaurtinib and increased leukemic cell death. 81 Resistance to FLT3 inhibitors can occur, primarily through upregulation of the FLT3 receptor, 82 point mutations 83 or increased FLT3 ligand levels. 60, 61 In vitro screens have identified four mutations in the ATP-binding pocket of FLT3 that confer varying degrees of resistance to FLT3 inhibitors. 83 FLT3 clones with mutations at alanine 627, asparagine 676 or phenylalanine remain sensitive to higher concentrations of most inhibitors, but a glycine-to-arginine mutation at position 697 conferred resistance to all nine tyrosine kinase inhibitors tested and, when it arises, may necessitate alternative therapeutic approaches. This crucial mutation at codon 697 has not been detected to date in patients with AML.
Upregulation of FLT3 in the presence of FLT3 inhibitors, on the other hand, has been observed in vitro 82 and in vivo. 56 In addition, the lestaurtinib combination trial illustrated that FLT3 ligand upregulation is another important clinical feature of resistance. It is clear that FLT3 ligand can interfere with tyrosine kinase inhibition of FLT3. 61 Myeloablative radiation and chemotherapy induce marked increases in FLT3 ligand. [84] [85] [86] This is especially problematic in heavily treated patients with relapsed disease. Further understanding of the mechanisms through which patients develop primary or secondary resistance to FLT3 inhibitors will help to guide how these agents should be incorporated into the treatment algorithm for AML.
In single-agent studies with FLT3 inhibitors, responses were limited to peripheral blast reduction. None of the inhibitors currently in development led to sustained cytogenic responses on their own, making combination therapy the preferred strategy for using these agents in patients with AML. Combination therapies may result in more durable responses through induction of faster and perhaps deeper responses and by thwarting FLT3-resistance mechanisms. In the trial of midostaurin plus induction (daunorubin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy, for example, disease-free survival and OS in FLT3-ITD patients was comparable to that of the more favorable FLT3-wild-type prognostic group. 54 
ALTERNATIVE STRATEGIES FOR FLT3 INHIBITION
After it was discovered that activated FLT3 is a marker of poor prognosis in AML, it was anticipated that inhibiting this target would significantly change the natural history of this disease. Unfortunately, none of the currently available FLT3 inhibitors have Role of FLT3 in AML R Swords et al met this expectation. This may be explained by the numerous FLT3-resistance mechanisms previously discussed in addition to the extremely heterogeneous nature of AML. 52, 56, 58, 83, 87, 88 Another important explanation is the failure of available FLT3 inhibitors to adequately inhibit their target. To overcome these problems, better drug delivery systems (for example, monocloncal FLT3 anitbodies) need to be developed and rational combination therapies need to be fully evaluated before we consider abandoning FLT3 as a target for the treatment of AML.
FLT3 monoclonal anitbodies
Monoclonal antibodies (mAbs) have shown significant efficacy in various cancers. 89 In AML, mAbs may be able to circumvent some of the common resistance mechanisms observed with FLT3-targeted agents. For example, improved specificity for FLT3 might offer less clinical toxicity in addition to the therapeutic benefits of ligand blockade, the potential for immunoconjugation and antibody-dependent cell-mediated cytoxicity. 87 Several putative FLT3 mAbs have been evaluated in the laboratory and are starting to be used in the clinic.
A number of fully human immunoglobulin anti-FLT3 mAbs, derived from fragments originally isolated from naïve human monovalent antibody fragment phage display libraries, have been developed. [90] [91] [92] [93] Agents such as IMC-EB10, D4-3 and IMC-NC7 bind to FLT3 with high affinity. 90 IMC-EB10 inhibits FLT3 ligandinitiated phosphorylation and activation of FLT3 in ITD-mutant FLT3 cell lines. 92 Target inhibition was demonstrated through in vitro interruption of MAPK, PI3K/AKT and signal transducer and activator of transcription 5 signaling, and prolonged survival was seen in IMC-EB10-treated mice with both wild-type and ITD-mutated FLT3. IMC-EB10 was also effective in leukemic blasts resistant to lestaurtinib. 87, 94 A phase 1 clinical trial is currently underway with this agent (ClinicalTrials.gov Identifier: NCT00887926).
To address the limitation of intracellular penetration of pure FLT3 mAbs, mAb-cytotoxin conjugates have been developed. Novel auristatin conjugates (using EB10 and a dolastatin analog, monomethyl auristatin F, linked with a protease-sensitive dipeptide 90, 95 ) specifically select for FLT3 þ cells, maintaining stability in the plasma but releasing the cytotoxic moiety once internalized and released by the cell lysosome. These agents and others 96, 97 are expected to be in clinical development soon.
Novel combination strategies Currently available FLT3 inhibitors have been combined effectively with established cytotoxic agents, both in the laboratory and in the clinic. 59, 98, 99 Ongoing clinical trials are exploring combination therapy with FLT3 inhibitors and agents with various mechanisms of action, including nucleoside analogs, mTOR inhibitors, proteasome inhibitors and C-X-C chemokine receptor type 4 (CXCR4) inhibitors (Table 4) . Other promising approaches might include MEK inhibitors, arsenic trioxide (ATO) or heat shock protein 90 (hsp90) inhibitors in combination with an FLT3 inhibitor.
CXCR4 inhibitors. CXCR4 and its ligand (chemokine stromal-derived factor 1a) are critical components of the stromal-leukemia cell interface. CXCR4 has an important role in cell adhesion-mediated drug resistance 100, 101 and, interestingly, is found more abundantly in FLT3-ITD AML samples than in FLT3-wild-type samples.
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CXCR4 inhibition results in disruption of AML-niche interactions and sensitizes leukemic blasts to cytotoxic chemotherapy. [103] [104] [105] Thus, CXCR4/FLT3 combination therapy might preferentially target FLT3-ITD cells. This combination is currently being evaluated in a phase 1 clinical trial.
MEK inhibitors. The MEK/MAPK pathway is downstream of FLT3 and is critical for the control of hematopoietic cell differentiation and proliferation. 27, 106 Consistent with this, MEK inhibition impairs the growth of FLT3-ITD cells 107 and leads to apoptosis in primary AML blasts. 108 Recent reports have demonstrated that MEK/MAPK inhibition can release cells from FLT3-ITD-mediated differentiation blockade. 109 These findings suggest that MEK is a rational target for combination studies with available FLT3 inhibitors.
Arsenic trioxide. Emerging preclinical reports of activity with ATO combined with a MEK inhibitor in primary AML 110 led to the discovery that ATO in combination with an FLT3 inhibitor (AG1296) could potently impair the growth of FLT3-ITD cell lines. 111 Given that ATO is well tolerated in the clinic, 112 this exciting combination is certainly worth exploring in clinical trials.
hsp90 inhibitors. hsp90 is a molecular chaperone for FLT3, 113 and hsp90 inhibition leads to FLT3 polyubiquitination and proteasomal degradation. 114 As hsp90 targets misfolded proteins generated by mutations, it is likely that FLT3-ITD proteins are unstable and require chaperoning by hsp90 in leukemic cells. On the basis of this rationale, the hsp90 inhibitor 17-AAG combined with an FLT3 inhibitor was an effective strategy in preclinical AML studies and is worth exploring in phase 1 trials. 115, 116 CONCLUSIONS/FUTURE DIRECTIONS Midostaurin and lestaurtinib are multitargeted kinase inhibitors that include FLT3 as one of their targets, whereas quizartinib is a highly selective FLT3 inhibitor, but is less cytotoxic to FLT3-ITD primary samples in vitro. These drug properties will likely dictate where these agents belong in the treatment algorithm. Quizartinib may be useful in relapsed patients, in whom high FLT3 ligand levels may necessitate a highly potent agent able to prevent ligand binding to FLT3. In newly diagnosed patients, broader spectrum agents such as midostaurin or lestaurtinib may be more appropriate. Novel agents that may have a role in the treatment of AML might include FLT3-ITD-specific small molecules and mAbs targeting FLT3. Another interesting approach might be to develop and incorporate mAbs targeting FLT3 ligand into the treatment algorithm for AML. Such antibodies may counteract the effects of FLT3 ligand upregulation during induction and consolidation chemotherapy.
AML is a heterogenous disease and, especially in early disease, multiple signaling pathways can contribute to pathogenesis. Combination approaches with novel agents and optimized algorithms may further improve outcomes in patients with AML. Upregulation of alternate kinase pathways can be a factor in resistance to FLT3 inhibitors, and agents targeting the Janus kinase /signal transducer and activator of transcription, phosphoinositide 3 kinase and mTOR families, for example, as well as other agents designed to interfere with the proteasome and other cell processes may have a role in combination with FLT3 inhibitors. Several of these combinations are currently being evaluated in clinical trials.
To fully eradicate AML in a patient, it may be necessary to eradicate AML stem cells. Novel approaches to AML treatment include the incorporation of stem cell mobilizers such as CXCR4 inhibitors and granulocyte-macrophage colony-stimulating factor into the treatment regimen. These agents may make AML stem cells more accessible for eradication by FLT3 inhibitors and chemotherapeutic agents. Proof of concept for this approach has been established in a mouse model of AML, 105 and combination therapies with FLT3 inhibitors and stem cell mobilizers are currently being evaluated in clinical trials.
The optimal timing and duration of FLT3 inhibitor therapy in the treatment algorithm for AML remain an open question. One potential strategy may be to use the FLT3 inhibitor early in the course of induction therapy, before FLT3 ligand levels rise, to improve the remission rate. The FLT3 inhibitor could be re-introduced as a maintenance therapy after achievement of remission once FLT3 ligand levels have returned to baseline. With such an approach, it may be possible to avoid transplant in some patients if durable remission is achieved with FLT3-targeting agents in combination with chemotherapy. In addition, because many centers recommend transplantation for eligible patients with FLT3-mutant AML in first complete remission, inhibitor therapy may have a role in maintaining complete remission before transplant and/or as a maintenance therapy to prevent relapse after transplant. Upcoming data from ongoing randomized trials with FLT3 inhibitors in patients with FLT3-mutant AML are eagerly awaited in order to begin to address these critical questions.
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